Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. - Wikidata - wikimedia - TriplyDB

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

http://www.wikidata.org/entity/Q37356046

about

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate Human papillomavirus related cervical cancer and anticipated vaccination challenges in Ethiopia Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2 Capsomer vaccines protect mice from vaginal challenge with human papillomavirus A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural Ethiopia HIV p24 as scaffold for presenting conformational HIV Env antigens.Optimization of multimeric human papillomavirus L2 vaccines.Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.Plant-based vaccines against viruses.Prevention of cancer by prophylactic human papillomavirus vaccines.Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Second-generation prophylactic HPV vaccines: successes and challenges.Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies HPV vaccination for prevention of skin cancer.A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine Progress and prospects for L2-based human papillomavirus vaccines Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.Virus-like particles for the prevention of human papillomavirus-associated malignancies.Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Virus-like particles produced in plants as potential vaccines.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Prophylactic HPV vaccination: past, present, and future.Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine.Developments in L2-based human papillomavirus (HPV) vaccines.HPV vaccines: Global perspectives.

P2860

Q24288709-3714AC2C-282B-4505-ABE8-B46AC0429A51 Q26752696-9B3DD882-A802-4DBC-9CC3-93EAB5909A4B Q27316846-BFA24415-89BB-4608-88E1-59E9E993E61A Q28280059-7B5A6B19-490C-4462-842A-E74DD264E5C0 Q28607775-D8AAB087-6ADA-4BEF-A2CD-5596439A8C54 Q28741364-FB3C33FA-2018-4AE4-9170-C3D1B2A0F3E8 Q28743261-D09CA4AC-5496-4010-BDA6-405A31330225 Q33572691-A602BED2-A7F8-4FCE-B9B7-B4BF6FEFAC19 Q33780651-E3696370-E6E0-4EAF-96EF-AE443FF8CBA4 Q33967341-F8BBEF55-BCD7-4B00-B6DD-A0CA8B468AED Q34259805-E8773658-DA86-416A-B98A-B21110BA3F45 Q34340212-EA261A96-0D66-411A-A6E6-B9BFF311A2D0 Q34389522-A12F46A2-339D-4A0A-BDDA-B7D6C94D0D49 Q34576677-1FAAC5B6-B376-4883-A128-7126732743BA Q34639978-9D2C2C73-50F1-49D1-9A7D-6C3DA60CCC7D Q34687464-BBABC825-7DFE-4AC5-9A4A-1D7ACAC2B189 Q34762053-344376D5-674E-4484-8C4F-DB2E77B08CD6 Q35532771-47756DA7-0490-4718-8828-2A5C9A7E48C7 Q35541886-D7BB3238-7088-460D-A005-EEB790088424 Q35773930-16BBD813-5982-49DA-A9C4-C7B618AAE617 Q35887782-0EB902D8-5F65-4551-B00C-67F3FE3619C9 Q36086265-D059B2D7-7EE9-4D69-BF4F-A3A638639EF2 Q36240497-EBF51B9D-7326-4D32-8212-00443715ED93 Q36970255-87C79B82-E870-4D54-8CBF-50F04E0CAC4B Q37014047-3FC7052D-28AD-4AA9-91AF-4213D4D1C4F7 Q37073299-78287784-C0EE-4967-936D-BE07649AE9AE Q37202927-92111E99-D9FB-4F92-9F7D-A6551791D5BD Q37219730-9DD44D4F-D69C-4B20-A1E1-FE8EDE51EE82 Q37274559-74D2712B-8B2D-45E7-BEDA-FD8261052018 Q37306139-DD5F21CD-1D8B-4715-BB5F-4619C28441AF Q37328475-582DB6FA-1E91-4741-BE1F-C21AC1B004C2 Q37599123-B23CCAB3-FC10-406A-B746-9B6A9DC3531D Q37665363-52E425C2-12FC-44A1-BDF2-9338BDE4133A Q37951525-B70FE28A-2AF6-4F26-8320-19A67DCD5463 Q38081975-0847FA8F-F1E7-4E24-A489-8C6B82B90A01 Q38370782-8C8C15CE-815C-4240-80ED-88A287CC2BB1 Q38597567-CF08E14A-9101-4328-B06C-8AA114156658 Q38682763-78CB7D83-DAA1-424C-8190-0B6316194A98 Q39021001-2EE5C17A-AE2A-4FF6-BEF9-2F3D4AE52D93 Q40265515-513F2F13-29B8-47BB-BF7F-4242EAD13568

P2860

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.

http://www.wikidata.org/entity/Q37356046

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Chimeric L1-L2 virus-like part ...... human papillomavirus vaccines.

@en

Chimeric L1-L2 virus-like part ...... human papillomavirus vaccines.

@nl

type

label

Chimeric L1-L2 virus-like part ...... human papillomavirus vaccines.

@en

Chimeric L1-L2 virus-like part ...... human papillomavirus vaccines.

@nl

prefLabel

Chimeric L1-L2 virus-like part ...... human papillomavirus vaccines.

@en

Chimeric L1-L2 virus-like part ...... human papillomavirus vaccines.

@nl

P1433

Q37356046-60D880B6-00FE-45E8-9DCD-47A273F71C8E

P1476

Q37356046-4B20F3F8-2994-441F-966F-FD5304B9FE42

P2093

Q37356046-10B48FE4-C65F-46B3-9654-9E7A29628DC5

Q37356046-34A6B5E3-4E47-4027-88A7-0E2A46D58C00

Q37356046-C5574546-0A15-4013-98D6-9B58BBF8467F

P2860

Q37356046-01F3D6AF-5C55-4B5F-AE0A-ADEE2EFB6D21

Q37356046-043828F8-3760-4159-9631-1873E0389A75

Q37356046-063B6D01-E9ED-451B-9EDC-1718505653D4

Q37356046-068DA909-BA1B-4982-9549-A6C58E35CC94

Q37356046-140ED81D-CECA-4ED3-903E-80B9E0A70303

Q37356046-1C2B0CF0-F0ED-4418-8B64-C4F79CBC8355

Q37356046-1CB3413A-29A1-49AC-94E6-86EC28FFDC50

Q37356046-1F4E6711-2D64-4DEC-849C-3DCFA23C0D2D

Q37356046-1FE3BDDA-1A6A-4A9C-AA46-11AAB4AF33AC

Q37356046-2C70BB52-8DD7-461A-AC15-C8777A4124A9

P304

Q37356046-EAC08A74-8C40-4AB2-AB24-0A4D6E85A494

P31

Q37356046-85641AA1-2441-44EB-9639-B8F580451E1C

P356

Q37356046-54EC8F39-526C-44EE-8CE1-EE055544679A

P407

Q37356046-7302F674-5C3A-4DDB-9792-84CA7ED29CCD

P433

Q37356046-6C76B77F-5185-43F0-A74C-112B00FB1884

P478

Q37356046-B5E3B7B7-C22F-4156-BB15-8605756CBC20

P577

Q37356046-E1F54D18-9345-44F6-A199-CA3DDD2EA655

P698

Q37356046-1C363C79-7505-4679-A411-9CD55225F2DC

P932

Q37356046-40491538-B971-4212-A2FE-0158C1552779

P356

P1433

Journal of Virology

P1476

Chimeric L1-L2 virus-like part ...... human papillomavirus vaccines.

@en

P2093

Christina Schellenbacher

http://www.w3.org/2001/XMLSchema#string

Reinhard Kirnbauer

http://www.w3.org/2001/XMLSchema#string

Richard Roden

http://www.w3.org/2001/XMLSchema#string

P2860

Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

Classification of papillomaviruses

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

P304

10085-10095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01088-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19640991

http://www.w3.org/2001/XMLSchema#string

P932

2748020

http://www.w3.org/2001/XMLSchema#string